Starling Oncology forecasts FY2026 revenue of $650-670 million - STLN News | RalliesStarling Oncology forecasts FY2026 revenue of $650-670 million
S
STLN• FY2026 revenue and EBITDA forecast
- Starling Oncology forecast FY26 revenue of USD 650-670 million, based on guidance reiterated in its Aug. 6, 2026 2Q26 release.
- Adjusted EBITDA expected at USD 2-7 million for FY26, implying a low single-digit margin on the revenue outlook.
- Forecast follows FY25 revenue of USD 503 million, with revenue mix led by specialty pharmacy at 54%.
- Growth backdrop includes 2.3 million value-based care lives under contract, 60+ payor contracts, 300,000+ encounters in 2025.
•
